Technology

RNA SEQUENCING

RNA sequencing (RNA-Seq) with next-generation sequencing (NGS) has revolutionized transcriptome research. It provides a high-resolution view into gene expression and regulators at both coding and noncoding regions. RNA-Seq offers numerous advantages over the traditional RT-PCR assay and gene expression array. It detects both known and novel features in a single assay, including changes in gene expression levels, gene fusions, alternative splicing events and single nucleotide variants. 

See Our Workflow and Platforms

WHAT WE OFFER

Whole Transcriptome Sequencing

Whole transcriptome sequencing showcases the expression levels of thousands of genes simultaneously, while also detecting novel transcripts, structural variations and unannotated exons important in revealing disease pathogenesis, molecular classification, treatment responses and prognosis. 

We offer two library preparation approaches to suit your research interests:

  • poly(A) enrichment of mRNA with main focus on protein-coding transcriptome 
  • rRNA depletion approach for human/mouse/rat RNA samples that keeps both coding and non-coding RNA to provide comprehensive transcriptome information

OUR WORKFLOW

A one-stop solution to your research

  • RNA sample quality control 
  • Library construction and quality control 
  • High-throughput sequencing 
  • Standard or customized bioinformatic analysis 
  • Secure cloud-based data delivery  
TURNAROUND TIME
  • 2-4 weeks* from receipt of samples in our sequencing facility 
*Longer turnaround time may be needed if a large number of samples are submitted. 
SAMPLE TYPES

Extracted total RNA

SEQUENCING PERFORMANCE SPECIFICATIONS
  • Platforms: NovaSeq 6000 
  • Read length: Pair-end 2 x 150bp 
  • Quality score: >80% of bases higher than Q30 

Sample Requisition

Sample Type 

Concentration* 

Total amount 

Other requirements 

Preferred Buffer 

Total RNA from cell lines or frozen/fresh tissues samples  ≥20 ng/ul  ≥200 ng  A260/280≥1.8; A260/230≥1.8

RIN≥7; No DNA contamination 

EB or TE buffer 
Total RNA from FFPE sample ≥40 ng/ul  ≥1 µg  A260/280≥1.8; A260/230≥1.8

RIN≥2; No DNA contamination 

EB or TE buffer 
*Sample quantities should be determined by fluorometric method (e.g. Qubit, PicoGreen). 

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us